Brokerages forecast that VIVUS, Inc. (NASDAQ:VVUS) will post ($0.13) earnings per share for the current quarter, Zacks reports. Zero analysts have issued estimates for VIVUS’s earnings. VIVUS posted earnings of ($0.09) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 44.4%. The company is scheduled to issue its next quarterly earnings report on Wednesday, November 8th.

On average, analysts expect that VIVUS will report full-year earnings of ($0.39) per share for the current fiscal year. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that cover VIVUS.

A number of research analysts have commented on VVUS shares. Zacks Investment Research raised VIVUS from a “hold” rating to a “buy” rating and set a $1.25 target price on the stock in a report on Thursday, July 27th. ValuEngine downgraded VIVUS from a “buy” rating to a “hold” rating in a report on Friday, September 1st.

VIVUS (NASDAQ:VVUS) traded down 3.85% on Wednesday, reaching $0.95. The company’s stock had a trading volume of 830,433 shares. VIVUS has a 52 week low of $0.86 and a 52 week high of $1.47. The firm’s 50 day moving average price is $0.98 and its 200-day moving average price is $1.09. The company has a market capitalization of $100.52 million, a price-to-earnings ratio of 3.06 and a beta of 0.88.

Several institutional investors have recently made changes to their positions in VVUS. Spark Investment Management LLC acquired a new stake in shares of VIVUS during the 2nd quarter worth approximately $100,000. Bank of New York Mellon Corp increased its position in VIVUS by 3.6% in the 1st quarter. Bank of New York Mellon Corp now owns 106,842 shares of the biopharmaceutical company’s stock valued at $120,000 after acquiring an additional 3,694 shares during the period. Russell Investments Group Ltd. increased its position in VIVUS by 84.8% in the 2nd quarter. Russell Investments Group Ltd. now owns 148,600 shares of the biopharmaceutical company’s stock valued at $180,000 after acquiring an additional 68,200 shares during the period. Northern Trust Corp increased its position in VIVUS by 16.8% in the 2nd quarter. Northern Trust Corp now owns 275,097 shares of the biopharmaceutical company’s stock valued at $335,000 after acquiring an additional 39,473 shares during the period. Finally, Oxford Asset Management increased its position in VIVUS by 76.6% in the 1st quarter. Oxford Asset Management now owns 587,535 shares of the biopharmaceutical company’s stock valued at $658,000 after acquiring an additional 254,912 shares during the period. Institutional investors and hedge funds own 35.82% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was first reported by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/09/20/zacks-analysts-expect-vivus-inc-vvus-will-post-earnings-of-0-13-per-share.html.

About VIVUS

VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).

Get a free copy of the Zacks research report on VIVUS (VVUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for VIVUS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.